Metraipolis › archive › dc_53343a8abe5f

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada — Europe PMC PMID:41744849

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41744849
DOI
10.3390/curroncol33020085
License (as archived)
solo-consultazione
Archived
2026-11-06T09:35:18.053Z
SHA-256 of the archived text
a5a7e7b36321400a50c9990b6e3e043ae6af3912094ea98ad09ea32756f15a9a
Stable URL of this page
https://metraipolis.com/documento/dc_53343a8abe5f

How to cite

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada — Europe PMC PMID:41744849 — Europe PMC (en), https://europepmc.org/article/MED/41744849 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_53343a8abe5f (Metraipolis archive dc_53343a8abe5f, sha256 a5a7e7b36321400a50c9990b6e3e043ae6af3912094ea98ad09ea32756f15a9a)
BibTeX
@misc{dc53343a8abe5f,
  title = {Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada — Europe PMC PMID:41744849},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41744849},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_53343a8abe5f; sha256 a5a7e7b36321400a50c9990b6e3e043ae6af3912094ea98ad09ea32756f15a9a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41744849. Agents can read the archived copy with the MCP tool read_document.